MedCity News November 12, 2024
Estelle Ricoux and Molly McGaughan

As radiopharmaceuticals enter a new phase, industry leaders must rethink external services and internal capabilities to master the complexities of delivering advanced therapies.

The radioligand therapy (RLT) space is entering a new era, as demonstrated by Eli Lilly’s recent $4.5 billion investment in a new research and manufacturing infrastructure. Pharmaceutical companies, typically focused on the development of intellectual property, are increasingly prioritizing their ability to produce, scale, and deliver these innovative treatments. Novartis has also doubled down on this shift, with an additional $200 million investment in the manufacturing of RLT and accompanying customer services. Together, these investments underscore the industry’s evolution towards mastering the intricate processes required for widespread RLT adoption, marking a new chapter in personalized cancer treatment.

...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
Bariatric Surgeons Being Put Out of Work by GLP-1 Drugs
The CMS NHE 2023 Report: An Incomplete Picture at a Pivotal Time
Pharma At A Crossroads: Navigating Cost Pressures And Regulatory Shifts In 2025
Why Walgreens Is Reportedly Considering a Private Equity Buyer
Gene Therapy Shows Long-Term Vision Benefits in Rare Eye Disease

Share This Article